The yearly trend of reported thyroid cancers associated with GLP‐1 receptor agonists shows a steady rate of approximately 40–50 cases per year from 2012 to 2022, as illustrated in Figure 1. This evidence concerns the gene GLP1R and thyroid gland carcinoma.